API Sourcing from India vs. China: What Buyers Are Considering
The question of sourcing Active Pharmaceutical Ingredients (APIs) from India versus China is one that procurement teams and formulation manufacturers across the world have been actively reassessing. This is not a simple India-wins or China-wins story — both countries have distinct strengths and limitations, and the right answer depends on the specific molecule, your market's regulatory requirements, and your supply risk tolerance.
This post outlines the key factors buyers typically weigh. It is an industry-landscape overview — not an endorsement of any sourcing position.
---
China's Historical API Dominance
China established a dominant position in global API manufacturing over several decades, driven by: - Large-scale production infrastructure with significant cost advantages - Vertical integration in chemical synthesis — from basic chemicals through intermediates to API - Broad product coverage across penicillin-based APIs, analgesics, vitamins, and many other categories
For many API categories, Chinese manufacturers still offer the lowest cost per kilogram globally, and the depth of product range available from Chinese API suppliers is substantial.
---
Why Buyers Are Diversifying Toward India
Several factors have prompted formulation manufacturers and buyers to evaluate Indian API sources more actively:
1. Supply chain resilience The COVID-19 pandemic revealed concentration risk in API supply chains that leaned heavily on a single geography. When Chinese manufacturing faced operational disruptions, downstream formulation manufacturers globally experienced supply shortfalls. Buyers seeking to reduce single-source dependency began qualifying Indian API manufacturers as alternative or primary sources. 2. Regulatory access For formulation manufacturers targeting US, EU, or other regulated markets, the API supplier must also hold appropriate regulatory approvals (US FDA, EU-GMP). India has a significant number of US FDA-approved API facilities — in some product categories, comparable to or exceeding the number of Chinese suppliers with equivalent approvals. For regulated-market formulations, Indian API manufacturers are often better positioned on regulatory documentation. 3. India's PLI scheme building capacity India's PLI scheme for KSMs, drug intermediates, and APIs (discussed in a separate post) is adding domestic manufacturing capacity in categories where India was import-dependent on China. This is a medium-term development — not yet fully reflected in current supply availability, but building. 4. Geopolitical considerations Trade policy uncertainty and the broader strategic question of supply chain geography have led some buyers to actively reduce dependence on China across industrial inputs, including pharmaceutical raw materials. This is a corporate risk management consideration, not a quality judgment.---
India's Limitations Relative to China
A balanced view requires acknowledging where Indian API manufacturing currently has limitations:
- Cost: For many commodity APIs, Chinese production costs remain lower than Indian equivalents. Indian API manufacturers have higher labour and regulatory compliance costs in some categories. - Range: China's breadth of API coverage — particularly in basic chemical-derived intermediates — exceeds India's current domestic range. India still imports significant volumes of intermediates from China for its own API production. - Scale in some categories: Fermentation-based APIs (penicillin, cephalosporins) are areas where Chinese capacity is very large; India's capacity exists but may be comparatively smaller in certain specific molecules.
---
The Practical Sourcing Approach
Most sophisticated pharmaceutical buyers are not choosing exclusively between India and China — they are dual-qualifying sources where commercially viable:
- Qualify both an Indian and a Chinese supplier for high-volume, strategically important APIs - Allocate volume based on price, availability, and regulatory status - Use the dual-source to negotiate better terms and maintain supply continuity
For buyers who source through Indian pharmaceutical traders rather than directly from API manufacturers, the trader's sourcing network matters — do they have established relationships with API-sourcing formulation manufacturers, and can they advise on product availability?
---
Contact Bharat Medex to discuss formulated medicine sourcing from India.
0 comments